Jennifer Mak Sells 77 Shares of Axon Enterprise (NASDAQ:AXON) Stock

Key Points

• Jennifer Mak, Chief Accounting Officer of Axon Enterprise, sold 77 shares at an average price of $760.00, totaling $58,520, which decreased her position in the company by 0.51%.
• Axon Enterprise reported a 32.6% increase in revenue year-over-year for the last quarter, with earnings per share of $2.12, exceeding estimates.
• Wall Street analysts rated Axon Enterprise with a Moderate Buy consensus and a target price of approximately $837.69, with many firms setting price objectives between $800 and $900.

Axon Enterprise, Inc (NASDAQ:AXON - Get Free Report) CAO Jennifer Mak sold 77 shares of the stock in a transaction on Monday, September 15th. The shares were sold at an average price of $760.00, for a total value of $58,520.00. Following the completion of the transaction, the chief accounting officer directly owned 15,003 shares in the company, valued at $11,402,280. This trade represents a 0.51% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Axon Enterprise Stock Up 0.6%

NASDAQ:AXON traded up $4.66 during trading hours on Monday, hitting $760.79. The company's stock had a trading volume of 391,514 shares, compared to its average volume of 683,694. The stock has a market capitalization of $59.72 billion, a P/E ratio of 187.85, a price-to-earnings-growth ratio of 27.75 and a beta of 1.40. The stock has a fifty day moving average of $761.10 and a 200-day moving average of $688.38. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63. Axon Enterprise, Inc has a 52-week low of $376.53 and a 52-week high of $885.91.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its earnings results on Monday, August 4th. The biotechnology company reported $2.12 EPS for the quarter, beating the consensus estimate of $1.54 by $0.58. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The firm had revenue of $668.54 million for the quarter, compared to analyst estimates of $641.77 million. During the same quarter in the prior year, the company posted $1.20 earnings per share. Axon Enterprise's revenue for the quarter was up 32.6% compared to the same quarter last year. Axon Enterprise has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Institutional Investors Weigh In On Axon Enterprise

Hedge funds and other institutional investors have recently modified their holdings of the stock. Hemington Wealth Management lifted its position in shares of Axon Enterprise by 70.8% during the 2nd quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company's stock valued at $33,000 after acquiring an additional 17 shares during the period. Whipplewood Advisors LLC raised its position in shares of Axon Enterprise by 192.9% during the 2nd quarter. Whipplewood Advisors LLC now owns 41 shares of the biotechnology company's stock worth $34,000 after purchasing an additional 27 shares during the last quarter. Darwin Wealth Management LLC acquired a new position in shares of Axon Enterprise during the 2nd quarter worth approximately $37,000. Fourth Dimension Wealth LLC acquired a new position in shares of Axon Enterprise during the 4th quarter worth approximately $30,000. Finally, NewSquare Capital LLC raised its position in shares of Axon Enterprise by 96.2% during the 2nd quarter. NewSquare Capital LLC now owns 51 shares of the biotechnology company's stock worth $42,000 after purchasing an additional 25 shares during the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on AXON. Northland Securities set a $800.00 price objective on shares of Axon Enterprise in a research note on Tuesday, August 5th. Craig Hallum upgraded shares of Axon Enterprise from a "hold" rating to a "buy" rating and set a $900.00 target price for the company in a research note on Tuesday, August 5th. Raymond James Financial reiterated an "outperform" rating and set a $855.00 target price (up previously from $645.00) on shares of Axon Enterprise in a research note on Tuesday, August 5th. Needham & Company LLC set a $870.00 target price on shares of Axon Enterprise and gave the stock a "buy" rating in a research note on Tuesday, August 5th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Axon Enterprise from $730.00 to $850.00 and gave the company an "overweight" rating in a research report on Thursday, July 17th. Thirteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat, Axon Enterprise currently has an average rating of "Moderate Buy" and a consensus price target of $837.69.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.